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Abstract
Myotonic dystrophy type 2 (DM2) is an auto-
somal dominant disorder caused by the expan-
sion of the tetranucleotidic repeat (CCTG)n in
the first intron of the Zinc Finger Protein-9
gene. In DM2 tissues, the expanded mutant
transcripts accumulate in nuclear focal aggre-
gates where splicing factors are sequestered,
thus affecting mRNA processing. Interestingly,
the ultrastructural alterations in the splicing
machinery observed in the myonuclei of DM2
skeletal  muscles  are  reminiscent  of  the
nuclear changes occurring in age-related mus-
cle  atrophy.  Here,  we  investigated  in  vitro
structural and functional features of satellite
cell-derived myoblasts from biceps brachii, in
the  attempt  to  investigate  cell  senescence
indices in DM2 patients by ultrastructural cyto-
chemistry. We observed that in satellite cell-
derived DM2 myoblasts, cell-senescence alter-
ations  such  as  cytoplasmic  vacuolization,
reduction  of  the  proteosynthetic  apparatus,
accumulation of heterochromatin and impair-
ment of the pre-mRNA maturation pathways
occur earlier than in myoblasts from healthy
patients. These results, together with prelimi-
nary in vitro observations on the early onset of
defective structural features in DM2 myoblast
derived-myotubes, suggest that the regenera-
tion capability of DM2 satellite cells may be
impaired,  thus  contributing  to  the  muscular
dystrophy in DM2 patients.
Introduction
Myotonic dystrophies (DMs) are autosomal
dominant  disorders  exhibiting  a  variety  of
multisystemic features among which muscular
dystrophy,  myotonia,  dilated  cardiomyopathy,
cardiac conduction defects, cerebral abnormal-
ities,  insulin-resistance,  and  cataracts;1-3 in
addition,  disease-specific  serological  abnor-
malities  are  present,  such  as  hyperglycemia
and increased levels of gamma-glutamyltrans-
ferase,4,5 hypotestosteronism,  and  decreased
levels of IgG and IgM immunoglobulin.6 The
more  frequent  and  severe  DM  form  is  the
DM1-Steinert’s  disease  (OMIM  160900),
which  affects  1:8000  individuals  worldwide,
and  is  caused  by  an  expanded  (CTG)n
nucleotide  sequence  in  the  3’  untranslated
region  of  the  Dystrophia  Myotonic  Protein
Kinase (DMPK) gene (OMIM 605377) on chro-
mosome 19q13.7-9 In 1999, a second DM form
displaying  a  milder  clinical  phenotype  has
been  identified:10 it  has  been  essentially
described in European Countries and has been
called DM2 (OMIM 602688); it is much less
frequent  than  DM1  since  it  affects  1:20000
individuals, although a recent genotypic study
on Finnish patients11 suggested that DM2 fre-
quency could be much higher than previously
estimated; it is caused by the expansion of the
tetranucleotidic  repeat  (CCTG)n  in  the  first
intron of the Zinc Finger Protein (ZNF-9) gene
(OMIM 116955)12 on chromosome 3q21.13
Due to its less severe phenotype, diagnosis
of DM2 is sometimes difficult and may be made
relatively later, compared to DM1; to face this
difficulty, the localization of ribonucleoprotein
(RNP)-enriched domains (called foci) in DM2
cell  nuclei  has  been  recently  proposed  as  a
rapid and reliable marker for recognizing sub-
jects affected by this pathology.14,15 In fact, in
tissues of DM2 patients, the expanded-CCUG-
containing transcripts are retained in the cell
nucleus and accumulate in the form of focal
aggregates.12 These  nuclear  foci of  mutant
mRNA  specifically  sequester  splicing  factors
among  which  muscleblind-like  (MBNL)  pro-
teins,14-17which are essential for the alternative
splicing for muscle cell proteins,18and the RNP-
containing  complexes  called  snRNPs  and
hnRNPs:19 this  leads  to  the  depletion  and/or
loss of function of these nuclear regulators.20
In a recent study, the distribution of nuclear
RNP-containing structures and molecular fac-
tors  responsible  for  pre-mRNA  transcription
and maturation has been described in myonu-
clei of dystrophic skeletal muscles,21 providing
evidence for alterations of post-transcriptional
pre-mRNA events as much as it occurs in the
myonuclei of skeletal muscles from old rats.22
These findings open interesting perspectives
for  comparative  studies  aimed  at  detecting
common cellular mechanisms responsible for
the loss of muscle mass, strength and function
typical of sarcopenia in aged individuals,23,24 as
well as for the muscle alterations caused by
DM2, which include fibre atrophy-hypertrophy,
increased number of centrally located nuclei,
and  the  presence  of  fibres  with  nuclear
clumps.3
A common hypothesis proposed to explain
skeletal  muscle  wasting  in  both  sarcopenia
and myotonic dystrophy implies a decreased
efficiency of muscle regeneration due to hin-
dered activation, proliferation and/or differen-
tiation capability of satellite cells.25-28
In  vitro myoblast  cultures  derived  from
human  satellite  cells  provide  a  suitable  and
unique model for studying DM2 muscular pre-
cursor cells, and can be used to elucidate the
molecular and cellular mechanisms involved in
the pathogenesis of this disease.29,30
In  this  work  we  have  investigated  some
structural and functional features of myoblasts
obtained  from  biceps  brachii biopsies  in  the
attempt to detect cell senescence traits in DM2
patients  in  comparison  with  healthy  control
subjects.  To  do  this,  satellite-cell-derived
myoblasts were grown in vitro, and underwent
several passages in culture: for sake of simplic-
ity, myoblasts at early (2nd and 3rd) passages
were defined as young in culture, while those at
late  (14th to  17th)  passages  were  defined  as
senescing. We have applied cytochemical and
Correspondence:  Manuela  Malatesta,  Diparti  -
mento  di  Scienze  Neurologiche,  Neuropsico  -
logiche,  Morfologiche  e  Motorie,  Sezione  di
Anatomia e Istologia, University of Verona, Italy.
E-mail: manuela.malatesta@univr.it
Key  words:  myotonic  dystrophy  type  2  -  DM2,
myoblasts, RNA processing, electron microscopy,
immunocytochemistry.
Acknowledgments:  the  authors  would  like  to
thank Mrs. Paola Veneroni for her skilful techni-
cal assistance. Marzia Giagnacovo is a PhD stu-
dent in receipt of a fellowship from the Dottorato
di  Ricerca  in  Biologia  Cellulare  (University  of
Pavia).  The  authors  would  also  express  their
gratitude to Prof. T.E. Martin for kindly providing
the anti-hnRNP core protein antibody.
Received for publication: 27 July 2011.
Accepted for publication: 5 September 2011.
This work is licensed under a Creative Commons
Attribution NonCommercial 3.0 License (CC BY-
NC 3.0).
©Copyright M. Malatesta et al., 2011
Licensee PAGEPress, Italy
European Journal of Histochemistry 2011; 55:e26
doi:10.4081/ejh.2011.e26[European Journal of Histochemistry 2011; 55:e26] [page 137]
immunocytochemical techniques at light and
electron microscopy as proved valuable tools for
studying  neuromuscular  diseases,  especially
when cell nuclear functions are involved.31-33 In
fact, in eukaryotic cells, maturation of mRNA
implies  that  the  primary  transcripts  (pre-
mRNAs) undergo several transformation steps
in the spliceosome, a molecular complex com-
posed  of  five  small  nuclear  RNPs  (snRNPs),
many non-snRNP splicing factors, and regulat-
ing  factors.34,35 The  structural  counterpart  of
such macromolecular complexes is represented
by RNP-containing structures named perichro-
matin  fibrils,  perichromatin  granules  and
interchromatin granules: the correct intranu-
clear distribution and molecular composition of
these structures is essential for mRNA matura-
tion, and their ectopic reorganization is a reli-
able sign of impaired nuclear activity.36-39
Materials and Methods
Sample collection
Samples  of  biceps  brachii muscles  were
taken  from  male  adult  patients  affected  by
DM2 (three subjects, aged 46-55) as well as
from three male healthy donors (aged 46-50),
after informed consent. The experimental pro-
tocols  have  been  approved  by  the  Ethical
Committee  of  the  IRCCS  Policlinico  San
Donato. All the subjects were in the adulthood
range,  and  this  allowed  excluding  the  influ-
ence  of  possible  aging-related  changes  in
nuclear  features.  The  histological  diagnosis
was performed on serial sections processed for
routine histological or histochemical staining,
based  on  the  clinical  criteria  set  by  the
International Consortium for Myotonic Dystro  -
phies.40 The biopsies were trimmed of blood
vessels, fat and connective tissues, and rinsed
in phosphate-buffered saline (PBS); satellite
cells were isolated as reported in Cardani et
al.29 and placed in HAM’s F10 medium (Sigma-
Aldrich,  Buchs,  Switzerland)  supplemented
with  15%  fetal  bovine  serum  (Gibco,
Invitrogen,  S.  Giuliano  Milanese,  Italy),  0.5
mg/mL  albumin  from  bovine  serum  (BSA,
Sigma-Aldrich), 0.5 mg/mL fetuin, 0.39 µg/mL
dexamethasone,  10  ng/mL  epidermal  growth
factor, 0.05 mg/mL insulin, 3 mg/mL glucose,
100  U/mL  penicillin  and  100  µg/mL  strepto-
mycin  (Sigma-Aldrich).  The  myoblasts
obtained by this procedure were propagated in
plastic flasks at 37°C in a humidified 95% air /
5% CO2 atmosphere. For transmission electron
microscopy, myoblasts were grown in flasks,
whereas  for  light  microscopy  the  myoblasts
were planted on glass coverslips in multiwell
plates (all the plastics were from Euroclone,
Milan, Italy).
Light microscopy
For  fluorescence  cytochemistry,  cells  on
glass coverslips were fixed with 4% formalde-
hyde in PBS for 15 min at 4°C, post-fixed with
70% ethanol at -20°C for 30 min, and rehydrat-
ed in PBS at room temperature (RT). 
To  specifically  label  myoblasts,  the  slides
were incubated for 60 min at RT with a mono-
clonal  antibody  recognizing  desmin  (Dako,
Glostrup, Denmark) diluted 1:100 in PBS con-
taining  0.1%  BSA  and  0.05%  Tween-20,  and
then incubated for 60 min at RT with an Alexa
488-conjugated  anti-mouse  IgG  (Molecular
Probes, Invitrogen), washed in PBS, counter-
stained for DNA with Hoechst 33258 (Sigma-
Aldrich; 1 ʼg/mL for 5 min), and mounted in
Mowiol  (Calbiochem,  Milan,  Italy).  500
desmin-positive cells per patient and passage
were scored for BrdU-positivity.
To  estimate  the  S-phase  fraction  of
myoblasts in the cell cultures, experiments of
BrdU  incorporation  were  performed.  Briefly,
cells  were  pulse-labeled  with  40  µM  BrdU
(Sigma)  for  2  h  at  37°C,  fixed  with  70%
ethanol for 30 min at -20°C, and incubated for
20 min at RT in 2 N HCl, to denature DNA par-
tially; after neutralization with 0.1 M sodium
tetraborate (pH 8.2) for 3 min, the slides were
washed in PBS, permeabilized for 15 min in
PBS containing 0.1% BSA and 0.05% Tween-20,
and incubated with the monoclonal antibody
recognizing  the  myoblast-specific  desmin,
revealed  with  an  Alexa  568-conjugated  anti-
mouse  IgG  (Molecular  Probes),  as  reported
above; after two washings with PBS, the slides
were then incubated for 1 h with an FITC-con-
jugated anti-BrdU mouse monoclonal antibody
(Clone  b44;  BD  Biosciences,  Beckton
Dickinson Italia, Milan, Italy) diluted 1:20. The
slides  were  finally  counterstained  for  DNA
with Hoechst 33258 (0.1 ʼg/mL for 10 min), to
be finally mounted with Mowiol (Calbiochem).
For  fluorescence  microscopy,  an  Olympus
BX51 microscope equipped with a 100W mer-
cury lamp was used, under the following condi-
tions: 330-385 nm excitation filter (excf), 400
nm dichroic mirror (dm), and 420 nm long-
pass filter, for Hoechst 33258; 450-480 nm excf,
500 nm dm, and 515-550 nm band-pass filter
for FITC; 540 nm excf, 580 nm dm, and 620 nm
long-pass filter, for Alexa 568. Digital images
were recorded with an Olympus Magnifire dig-
ital camera system, and stored on a PC by the
Olympus software, for processing and printing.
The same Olympus BX51 microscope previ-
ously described was also used for phase con-
trast microscopy, under the appropriate condi-
tions;  in  this  case,  micrographs  were  taken
with an Olympus Camedia 5050 digital camera.
The percentage of myoblasts containing vac-
uoles was estimated on 25 randomly selected
microscope  fields  per  sample  using  a  40x
objective  lens;  at  least  500  cells  per  sample
were considered. 
In order to provide in situ evidence for the
presence of senescent myoblasts, b-galactosi-
dase was detected according to Dimri et al.41 In
brief, samples were washed in PBS and fixed
with  2%  paraformaldehyde  and  0.2%  glu-
taraldehyde in 0.1 M PBS, pH 7.4, for 7 min at
RT. After, cells were incubated for 18 h at 37°C
in fresh senescence associated SA-b-gal stain-
ing  solution  [1  mg/mL  5-bromo-4-chloro-3-
inolyl-b-D-galactoside  (X-gal)  in  dimethylfor-
mamide  (20  mg/mL  stock);  40  mM  citric
acid/sodium phosphate, pH 6.0; 5 mM potassi-
um ferrocyanide; 150 mM NaCl; 2 mM MgCl2].
After 2 washings in PBS, cells were mounted in
a drop of Mowiol.
Transmission electron microscopy
Myoblasts at early (2nd- 3rd) and late (14th to
17th) passages (as defined after BrdU-incorpo-
ration experiments, see Results) were fixed in
the flasks and then collected by scraping. For
conventional morphology, cells were fixed with
2.5% glutaraldehyde and 2% paraformaldehyde
in 0.1 M Sörensen phosphate buffer at 4°C for
1 h, washed, post-fixed with 1% OsO4at 4°C for
2 h, dehydrated with acetone and embedded in
Epon.  For  immunoelectron  microscopy,  cells
were fixed with a mixture of 4% paraformalde-
hyde  and  0.2%  glutaraldehyde  in  0.1  M
Sörensen  phosphate  buffer  at  4°C  for  1  h,
washed,  treated  with  NH4Cl  0.5  M  in  PBS,
dehydrated with ethanol and embedded in LR
White resin. 
Ultrathin  sections  from  Epon-embedded
samples  were  conventionally  stained  with
uranyl acetate and lead citrate.
Ultrathin sections from LR White-embedded
samples were placed on Formvar-carbon coated
nickel  grids  and  processed  for  immunocyto-
chemistry. The sections were treated with the
following probes: mouse monoclonal antibod-
ies directed against the phosphorylated, acti-
vated  form  of  RNA  polymerase  II  (Research
Diagnostic  Inc.,  Flanders,  NJ,  USA)  or  the
(Sm)snRNP (small nuclear RNP) core protein
(Abcam,  Cambridge,  MA,  USA);  rabbit  poly-
clonal antibodies directed against the cleavage
stimulation factors CStF;42 chicken antibodies
directed  against  the  heterogeneous  nuclear
RNP  (hnRNP)  core  protein.43 Sections  were
floated for 3 min on normal goat serum (NGS)
diluted 1:100 in PBS and then incubated for 
17 h at 4°C with the primary antibodies dilut-
ed  with  PBS  containing  0.1%  bovine  serum
albumin  (Fluka)  and  0.05%  Tween  20.  After
rinsing,  sections  were  floated  on  NGS  and
were then allowed to react for 30 min at RT
with the appropriate secondary (either 6nm- or
12nm-gold-conjugated)  antibodies  (Jackson
ImmunoResearch  Laboratories  Inc.,  Suffolk,
UK) diluted 1:10 in PBS. Finally, the sections
Original paper[page 138] [European Journal of Histochemistry 2011; 55:e26]
were rinsed and air-dried. As controls, some
grids were incubated without the primary anti-
body and then processed as described above.
To reduce chromatin contrast and selectively
reveal nuclear RNP constituents, the sections
were  bleached  by  the  EDTA  method44 and
observed in a Philips Morgagni TEM operating
at 80kV and equipped with a Megaview II cam-
era for digital image acquisition. 
Quantitative assessment of the immunola-
belling was carried out by estimating the gold
grain density over the nucleoplasmic region on
sections treated in the same run. As for anti-
snRNP antibody, the labelling density was eval-
uated also on interchromatin granule clusters.
The grain densities were measured on fifteen
randomly  selected  electron  micrographs  (x
22,000)  of  myonuclei  from  each  patient  by
using a computerized image analysis system
(AnalySIS  Image  processing,  Soft  Imaging
System GmbH, Munster, Germany). For back-
ground  evaluation,  samples  treated  in  the
absence of primary antibody were considered.
Gold grains present over the selected compart-
ments were counted and the labelling density
was  expressed  as  the  number  of  gold
grains/ʼm2. 
In addition, the percentage of the nuclear
surface occupied by heterochromatin and the
perichromatin  granules  density  (PG
number/ʼm2 of nucleoplasm) were calculated
by using the same image analysis system. 
Statistical comparisons were performed by
the two-way ANOVA test to evaluate the influ-
ence of two factors: the presence of the dys-
trophic condition (we called this factor dystro-
phy, in Tables 1 and 2) and the increasing pas-
sages  in  culture  (cell senescing  in  vitro,  in
Tables 1 and 2); in addition, the interaction
term between these two factors was also con-
sidered. The one-way ANOVA test was used to
compare  the  immunolabelling  density  on
interchromatin  granules  between  myoblasts
samples from dystrophic or healthy patients at
early and late passage. Statistical significance
was set at P<0.05.
Results
In primary culture from skeletal muscles, a
fraction  of  fibroblasts  is  always  present  and
myoblasts  can  be  recognized  by  their
immunopositivity for the muscle specific pro-
tein, desmin (Figure 1a, a’). In the cultures
used  in  the  present  investigation,  the  myo-
genic index was always fairly high and ranged
from about 60% at the 2nd-3rd passage to more
than 90% at the 14th-17th passage, without sig-
nificant difference between control and DM2
cell populations. 
At low (2nd-3rd) passages from the explant,
desmin-positive  myoblasts  had  an  S-phase
fraction ranging from 20-26% in both control
and  DM2  cultures,  as  estimated  after  BrdU-
incorporation  experiments.  Myoblasts  were
considered as senescing at late (14th to 17th)
passages when the percentage of BrdU-posi-
tive, S-phase cells dropped to less than 5% and
2%, in control and DM2 myoblasts respectively.
This suggests that the decrease in the S-phase
fraction  is  faster  in  DM2  than  in  control
myoblasts.  Consistently,  the  percentage  of
beta-galactosidase  positive  cells  was  higher,
with  a  much  stronger  intensity  of  the  final
reaction products, in senescing DM2 than in
healthy myoblasts (about 90 and 80% of posi-
tive cells, respectively).
At  light  microscopy  (Figure  1),  myoblasts
from both control and DM2 patients appeared
as thin elongated cells with a centrally located
nucleus.  Phase  contrast  microscopy  showed
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Figure 1. Phase contrast and fluorescence micrographs of myoblasts from healthy (a,a’
and b,b’) and DM2 patients (c,c’ and d,d’) at early (a and c) and late (b and d) passages
in culture, after immunolabeling for desmin. In a’, the myoblast (arrow) may be distin-
guished from the fibroblast for its thin and elongated shape, and the immunopositivity
for desmin (green fluorescence). Nuclear DNA was counterstained with Hoechst 33258
(blue fluorescence). Note the cytoplasmic vacuoles (arrowheads) in DM2 myoblasts (c,d).
Scale bar: 20 µm.[European Journal of Histochemistry 2011; 55:e26] [page 139]
that about 15% of young DM2 myoblasts exhib-
ited small roundish vesicles in their cytoplasm
(Figure 1c), which were on the contrary rarely
found in the controls (less than 4%) (Figure
1a). At late passages, vacuolization of senesc-
ing DM2 myoblasts became much more appar-
ent  (about  30%  of  myoblasts  contained  vac-
uoles),  with  large  portions  of  the  cytoplasm
often occupied by huge vacuoles and devoid of
desmin  (Figure  1d);  about  10%  of  the
myoblasts  in  senescing  controls  (Figure  1b)
also showed small vacuoles in the cytoplasm,
although  there  was  never  evidence  of  the
extensive  cytoplasm  degeneration  found  in
senescing  DM2  myoblasts.  At  electron
microscopy, myoblasts were identified by their
elongated  shape  and  the  organelle  features
already described in literature.45-49
In the cytoplasm of young control myoblasts
(Figure 2 a-c), ovoid or elongated mitochon-
dria,  large  amounts  of  free  ribosomes,  well
developed  rough  endoplasmic  reticulum  and
numerous  Golgi  complexes  were  observed;
conversely, lysosomes, residual bodies and vac-
uoles were only seldom found. Myoblast nuclei
were generally characterised by a thin hete-
rochromatin  rim  just  beneath  the  nuclear
envelope  and  one  reticular  nucleolus  with
many fibrillar centres and abundant dense fib-
rillar component (the latter component is the
site  of  pre-rRNA  transcription  and  splicing)
(for a recent review on nucleolar components,
see50). Senescing control myoblasts (Figure 2
d-f) were even more elongated than at early
passages.  In  the  cytoplasm,  the  organelles
belonging  to  the  proteosynthetic  apparatus
and the mitochondria were abundantly pres-
ent;  in  addition,  glycogen  clusters,  residual
bodies and vacuoles - even of large size - were
frequently observed. Myoblast nuclei showed
increased heterochromatin amounts along the
nuclear  border,  while  the  nucleoli  appeared
unchanged in comparison to early passages.
Young  DM2  myoblasts  (Figure  3  a-c)  were
quite similar to the controls, apart from the
occurrence of differently sized vacuoles in the
cytoplasm, and larger amounts of heterochro-
matin  and  higher  density  of  perichromatin
granules in the nucleus (Figure 4 and Table 1,
for the statistical analysis).
Senescing DM2 myoblasts at late passages
(Figure 3 d-f) had very elongated shapes and
one elongated nucleus with an often irregular
border.  In  the  cytoplasm  many  vacuoles  and
large  electron  lucent  areas  were  abundantly
present; mitochondria, free ribosomes, rough
endoplasmic  reticulum  and  Golgi  complexes
were markedly reduced in comparison to the
early  passages,  while  glycogen  clusters  and
residual  bodies  were  abundant  and  ubiqui-
tously distributed. Myoblast nuclei frequently
showed  irregular  shapes  and  evident  hete-
rochromatin clumps, and most of the nucleoli
showed a reticular structure.
Observation  of  EDTA-stained  samples
showed  that,  in  all  patients,  the  usual  RNP
structural constituents involved in pre-mRNA
transcription and processing were evident in
the  nucleoplasm:  perichromatin  fibrils  and
perichromatin  granules  were  mostly  distrib-
uted in the perichromatin region, and inter-
chromatin  granules  formed  clusters  in  the
interchromatin  space.36,37 Immunolabelling
experiments  showed  a  similar  intranuclear
distribution of polymerase II, hnRNPs, snRNPs
and cleavage factor CStF in control and DM2
myoblasts  at  both  early  and  late  passages.
Activated  polymerase  II,  hnRNPs  and  CStF
were  specifically  associated  with  perichro-
matin fibrils (Figures 5 and 6), which repre-
sent the form in situ of pre-mRNA transcrip-
tion, splicing and 3’-end processing,36,37 while
snRNPs were restricted to perichromatin fib-
rils and interchromatin granules, which repre-
sent the storage, assembly and phosphoryla-
tion sites for transcription and splicing factors
(Figure 6).51,52 
Quantitative  evaluation  of  the  immunola-
belling (Figure 7) revealed that both factors,
dystrophy and cell senescing in vitro, signifi-
cantly influence the labelling values for all the
parameters  analysed;  moreover,  the  interac-
tion term was always significant indicating a
relationship  between  the  changes  during  in
vitro senescence and the healthy or diseased
origin of the cells; in fact, DM2 was always
associated with lower levels for all the parame-
ters analysed (Table 2). Anti-snRNP labelling
density  on  interchromatin  granule  clusters
was  significantly  higher  in  young  than  in
senescing control myoblasts (120.53±10.04 vs
48.49±3.01  gold  grains/µm2,  respectively;
P<0.001);  conversely,  in  DM2  myoblasts  the
values were similar at early and late passages
(67.86±7.98  vs 69.59±6.92  gold  grains/µm2,
respectively;  P=0.889).  Background  values
were negligible in all immunolabelling experi-
ments (not shown).
Discussion
The multifactorial phenotype of DM2, con-
sisting of muscle weakness and atrophy, and
the wide spectrum of extramuscular manifes-
tations  strongly  support  the  hypothesis  of  a
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Figure 2. Young (a-c) and senescing (d-f) healthy control myoblasts. (a) The myoblast
shows an elongated shape and one ovoid nucleus with a reticular nucleolus (Nu) and
scarce heterochromatin. In the cytoplasm, rough endoplasmic reticulum (arrows) and a
Golgi complex (g) are visible. Scale bar: 1 µm. (b,c) Cytoplasmic details showing free ribo-
somes (asterisk), well developed rough endoplasmic reticulum (arrows), numerous Golgi
complexes (g) and ovoid mitochondria (m). Vacuoles (v) are quite scarce. Bars: 2 µm. (d)
The myoblast shows a very elongated shape and one elongated nucleus with scarce hete-
rochromatin. In the cytoplasm, rough endoplasmic reticulum (arrows), residual bodies (r)
and vacuoles (v) are visible. Scale bar: 2 µm. (e,f) Cytoplasmic details showing free ribo-
somes (asterisk), ovoid mitochondria (m), a Golgi complex (g), a residual body (r) and
clustered glycogen granules (star). Scale bars: 1 µm.[page 140] [European Journal of Histochemistry 2011; 55:e26]
multisystemic syndrome caused by a general
alteration of the pre-mRNA post-transcription-
al  pathway.53-55 However,  the  cellular  mecha-
nisms leading to the highly variable clinical
manifestations in the different tissues of DM2
patients have not been clarified yet. In particu-
lar, at the skeletal muscle level, no explanation
for the muscle wasting has so far been found.
It has been hypothesised that, in dystrophic
muscle  tissue,  the  myogenic  potential  is
altered,  probably  in  relation  to  a  hindered
regenerative capability of satellite cells.25,28,56-59
Interestingly,  a  similar  hypothesis  has  been
also proposed to explain sarcopenia, i.e. the
age-related  loss  of  muscle  mass  and  func-
tion;23,24 in addition, recent data on dystrophic
skeletal muscle myonuclei21 have demonstrat-
ed alterations of mRNA pathways reminiscent
of those observed during aging.22 This strongly
suggests a common mechanistic basis for both
skeletal muscle aging and dystrophy.
Consistent  with  this  hypothesis,  the  mor-
pho-functional  features  of  myoblasts  from
healthy and DM2 patients at different passages
in culture provided experimental evidence for
the  more  pronounced  occurrence  of  senes-
cence-related events in satellite cells of DM2-
affected  muscles.  At  early  culture  passages,
when cell proliferation rate is high, both con-
trol and DM2 myoblasts show the typical mor-
phological features of growing myoblasts pre-
viously described by several authors, i.e. cells
characterised by elongated shapes, cytoplasm
rich  in  free  ribosomes,  rough  endoplasmic
reticulum  and  Golgi  complexes,  nuclei  with
scarce heterochromatin and prominent nucle-
oli.45-49 At this culture stage, the only distinc-
tive morphological feature of DM2 myoblasts is
the presence of several vacuoles in the cyto-
plasm which could be related to a dysregula-
tion  of  the  protein  degradation  systems  in
these  cells.60 Therefore,  cytoplasmic  and
nuclear features clearly indicate a high pro-
teosynthetic  rate  in  both  control  and  DM2
myoblasts at early compared to late passages;
in particular, the large amount of euchromatin
and the presence of reticular nucleoli with a
large dense fibrillar component and numerous
Original paper
Figure 3. Young (a-c) and senescing (d-f) DM2 myoblasts. (a) The myoblast shows an elon-
gated shape and one ovoid nucleus with a reticular nucleolus (Nu) and scarce heterochro-
matin. In the cytoplasm, rough endoplasmic reticulum (arrows), a Golgi complex (g) and
many vacuoles (v) are visible. Scale bar: 2 µm. (b,c) Cytoplasmic details showing well
developed rough endoplasmic reticulum (arrows), Golgi complexes (g), free ribosomes,
elongated  mitochondria  (m),  and  many  vacuoles  with  heterogeneous  content  (v).
Cytoplasmic electron lucent areas (stars) sometimes occur. Scale bars: 1 µm. (d) The
myoblast shows a very elongated shape and one irregularly shaped nucleus with evident
heterochromatin. In the cytoplasm, well developed Golgi complexes (g), and vacuoles (v)
are visible. Scale bar: 2 µm. (e) Large cytoplasmic regions are filled with heterogeneous
vacuoles (v) or appear as electron lucent areas (stars). Scale bar: 2 µm. (f) Cytoplasmic
detail showing rough endoplasmic reticulum (arrow), Golgi complexes (g), glycogen clus-
ters (star) and numerous vacuoles (v). Scale bar: 1 µm.
Table 1. Two-way ANOVA test of the mor-
phometric  evaluation  of  heterochromatin
percentage  and  perichromatin  granule
density (PG number/ʼm2 of nucleoplasm)
in  myoblasts:  factor  Dystrophy (healthy
and  DM2),  factor  Cell  senescing  in  vitro
(early  and  late  passage),  and  interaction
term (Dystrophy - Cell senescing in vitro).
Heterochromatin %
Dystrophy P<0.001
Cell senescing in vitro P=0.031
Interaction term P=0.042
PG density
Dystrophy P=0.063
Cell senescing in vitro  P=0.001
Interaction term P=0.001
Figure 4. Mean ± SE values of heterochro-
matin percentage and perichromatin gran-
ule  density  (PG  number/µm2 of  nucleo-
plasm)  in  myoblasts  from  healthy  and
DM2 patients (n=45).[European Journal of Histochemistry 2011; 55:e26] [page 141]
fibrillar centres are suggestive of a high meta-
bolic  activity.50 However,  the  ultrastructural
immunocytochemical  analyses  revealed  that
DM2 myoblasts are relatively less active than
the controls: the immunolabeling for activated
polymerase I (which is necessary to synthesize
pre-mRNA), for hnRNPs and snRNPs (which
are essential for pre-mRNA co-transcriptional
splicing34,35), and for CStF (involved in the mat-
uration  of  3’  ends61),  were  all  significantly
lower  in  DM2  than  in  control  myoblasts.
Accordingly,  morphometrical  evaluations
demonstrated  an  increase  in  the  amount  of
heterochromatin in DM2 myoblasts, consistent
with the already described reduction in protein
synthesis.60
A similar decrease in the factors involved in
pre-mRNA transcription and maturation, and a
parallel increase in the amount of heterochro-
matin have been found in senescing control
myoblasts,  when  the  proliferation  rate
decreased. However, no significant change in
perichromatin granule density has been found
in senescing control myoblasts: these granules
represent  storage  and/or  transport  sites  for
spliced (pre-)mRNA36 and their steady number
indicates  unperturbed  RNA  pathways.
Moreover, these control myoblasts are charac-
terised  by  the  presence  of  residual  bodies,
many vacuoles and glycogen clusters: these are
typical features of aging cells, where the cyto-
plasmic degradation systems undergo dysfunc-
tion.62 Thus, DM2 myoblasts at early culture
passages (when they proliferate at a similar
rate as the controls) already show some mor-
phological  and  functional  features  found  in
healthy myoblasts at late culture passage only. 
The cytoplasmic and nuclear features typical
of  cells  senescing  in  culture  are  definitely
more pronounced in DM2 myoblasts at late cul-
ture  passage  than  in  the  corresponding
healthy controls. The amount of vacuoles and
residual bodies is remarkably high, and large
cytoplasmic  regions  appear  as  empty,  likely
due to degradation phenomena; the cell nuclei
are often irregular in shape and contain many
heterochromatin clumps; the factors involved
in pre-mRNA transcription and processing are
further  reduced  in  comparison  to  senescing
healthy myoblasts. It should be also noted that
snRNPs,  usually  occurring  on  perichromatin
fibrils and interchromatin granules, show an
accumulation in the interchromatin granules
which  has  not  been  observed  in  senescing
healthy myoblasts. Intranuclear accumulation
of  factors  involved  in  pre-mRNA  maturation
has  been  previously  observed  in  different
aging tissues63-65 including skeletal muscle,22,66
and  this  has  been  considered  as  a  conse-
quence of altered pre-mRNA processing and/or
impaired intranuclear or nucleus-to-cytoplasm
transport.  Accordingly,  in  senescing  DM2
myoblasts a significant increase in perichro-
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Figure 5. Myoblasts from healthy (a,b) and DM2 (c,d) patients at early (a,c) and late (b,d)
passages. Anti-polymerase II (6 nm) and anti-CStF (12 nm) antibodies: both probes
specifically label perichromatin fibrils (arrowheads), while the interchromatin granules
(ig) are devoid of signal. Arrows indicate perichromatin granules. Ch: bleached hetero  -
chromatin. Scale bars: 0.25 µm.
Figure 6. Myoblasts from healthy (a,b) and DM2 (c,d) patients at early (a,c) and late (b,d)
passages. Anti-snRNP (6 nm) and anti-hnRNP (12 nm) antibodies: both probes label
perichromatin fibrils (arrowheads); in addition, the anti-snRNP antibody strongly labels
interchromatin  granules  (ig).  Arrows  indicate  perichromatin  granules.  Ch:  bleached
hetero  chromatin. Scale bars: 0.25 µm.[page 142] [European Journal of Histochemistry 2011; 55:e26]
matin  granule  amount  has  been  found;  this
phenomenon is known to occur when RNA pro-
cessing  is  physiologically  or  experimentally
impaired39,67,68 as well as during aging.22,63-66,69
Taken together, the results of the present study
demonstrate  that  satellite  cell-derived  DM2
myoblasts  are  characterised  by  senescence-
related features mainly consisting in the early
appearance  of  cytological  alterations  and
impairment of the pre-mRNA maturation path-
ways. It is possible that the sequestration of
splicing factors in the foci of DM2 myoblasts14-19
may  hamper  the  functionality  of  the  whole
splicing  machinery;  this  would  consequently
reduce, in dystrophic muscles, the capability of
satellite cells to positively respond to anabolic
stimuli. Interestingly, experimental therapeu-
tic  approaches  for  DM1  aimed  at  reducing
intranuclear sequestration of splicing factors
demonstrated that the restoration of normal
splicing processes represents a key passage for
alleviating disease symptoms.70,71
It has been reported that alteration of the
RNA  pathways  does  not  affect  the  fusion
process, so that cultured DM2 myoblasts are
able to differentiate into myotubes as much as
myoblasts  from  healthy  subjects  do.29,72
Similarly,  cultured  myoblasts  from  aged
healthy subjects are able to form myotubes in
culture.49 This would suggest that the capabili-
ty of cultured myoblasts to proliferate and dif-
ferentiate is maintained in aged and dystroph-
ic subjects. However, the present ultrastructur-
al and cytochemical data demonstrate that sig-
nificant differences exist for some cytological
and functional characteristics in the myoblasts
from healthy and DM2 patients, despite their
similarities in proliferation rate and age in cul-
ture. Interestingly, recent preliminary observa-
tions on the in vitro differentiation of DM2
myoblasts showed an early structural disorgan-
ization of the derived myotubes, especially the
cytoskeletal apparatus, which may affect their
functionality and survival.73
Further  studies  are  however  needed  to
investigate  in  vitro myoblast  differentiation
and myotube survival in DM2 patients using
both morphological and biomolecular analyses
such as those previously used to characterise
the differentiation process of C2C12 myoblast
cell line.74 Moreover, studies on the occurrence
of senescence traits in both satellite cells and
myofibres in DM2 muscle biopsies75 would pro-
vide important clues in the attempt to charac-
terize the cellular mechanisms at the basis of
muscle wasting in DM2 myotonic dystrophy.
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